Get the Stockscreener App
15.26
4.08%
-0.69
Denali Therapeutics Inc stock is traded at $15.26, with a volume of 74,295.
It is down -4.08% in the last 24 hours and down -28.20% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$15.95
Open:
$15.86
24h Volume:
74,295
Relative Volume:
0.08
Market Cap:
$2.30B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-5.3544
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-5.96%
1M Performance:
-28.20%
6M Performance:
-50.28%
1Y Performance:
-26.79%
1-Day Range:
$15.27
$16.16
1-Week Range:
$14.20
$16.97
52-Week Range:
$14.20
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8548
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
15.27 | 2.30B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.02 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.39 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.49 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.10 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Denali's ALS programme suffers another setback - pharmaphorum
What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks
Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks
DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - Marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World
DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating - Marketscreener.com
Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating - Marketscreener.com
Denali Therapeutics: Why Analysts Remain Optimistic - TipRanks
Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair - Defense World
What is HC Wainwright’s Forecast for DNLI Q1 Earnings? - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 - Defense World
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - MSN
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey
Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
William Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing - MSN
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating - Marketscreener.com
Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating - TipRanks
Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating - TipRanks
Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Denali Therapeutics reports Q4 EPS (67c), consensus (85c) - TipRanks
Denali Therapeutics Files For Mixed Shelf Size Not DisclosedSEC Filing -February 27, 2025 at 05:14 pm EST - Marketscreener.com
Denali Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Denali Therapeutics Signs New Equity Distribution Deal - TipRanks
Denali Therapeutics Inc. SEC 10-K Report - TradingView
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Can Denali's Hunter Syndrome Drug Breakthrough Offset $422M Annual Loss? - StockTitan
Trading (DNLI) With Integrated Risk Controls - Stock Traders Daily
Denali Therapeutics (DNLI) to Release Earnings on Tuesday - Defense World
Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Baillie Gifford & Co. Sells 1,031,956 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Tuesday - MarketBeat
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight - GlobeNewswire Inc.
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):